CJC-1295 (no DAC) + Ipamorelin
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
This research preparation pairs CJC-1295 (no DAC), a GHRH analog, with ipamorelin, a selective growth-hormone secretagogue (GHS-R/ghrelin-receptor agonist). The combination is studied on the rationale that the two act on distinct receptors converging on pituitary somatotrophs to amplify pulsatile growth-hormone release.
Combination-specific clinical data are limited; see the individual component entries.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797.
Trademarks & attribution
CJC-1295 originated at ConjuChem Biotechnologies and ipamorelin (NNC 26-0161) from Novo Nordisk research; neither has an approved trademarked drug product. Catalyst Research Labs is not affiliated with these organizations. Supplied as reference material only.
